All-trans-retinoic acid syndrome

Changed by Liz Silverstone, 30 Aug 2023
Disclosures - updated 6 Dec 2022: Nothing to disclose

Updates to Article Attributes

Body was changed:

All-trans-retinoic acid (ATRA) syndrome, is the more common cause of differentiation syndrome 8. Acute promyelocytic leukaemia (APL) cells respond to therapeutic levels of this normal plasma derivative of vitamin A by maturating into normal granulocytes which can cause capillary leakage and organ damage 1.

Terminology

More recently differentiation syndrome is the preferred term as other anti-leukaemia drugs are implicated. Arsenic trioxide (ATO) is often used in combination with ATRA and contributes to the development of this syndrome.

Isocitrate dehydrogenase (IDH) inhibitors cause this syndrome in acute myeloid leukaemia (AML) patients.

Epidemiology

Incidence is approximately 25% in APL patients treated with ATRA +/- ATO and 20% in AML patients treated with IDH inhibitors.

Pathology

Differentiation syndrome is related to the rapid increase in mature granulocytes over several days resulting in vascular adherence and organ infiltration. Cytokine release can cause capillary leak, haemorrhage and organ failure and these effects can be blocked by corticosteroids. Mortality can be as high as 25% and is commonly due to heart failure, acute respiratory distress syndrome, pulmonary haemorrhage and renal failure 1.

Clinical presentation

Differentiation syndrome occurs approximately 7 days after treatment initiation with features of fever, congestive heart failure, fluid-retention, respiratory distress, haemorrhage, thrombosis and renal failure.

Radiographic features

Cardio-pulmonary disease dominates the radiographic picture.

Plain radiograph

NonImaging appearances are non-specific chest radiographic featuresbut can alerthelp to confirm the clinical team to the possibilitysuspicion of differentiation syndrome: 

CT

Chest CT may show features of congestive heart failure, acute lung injury and pulmonary haemorrhage:

  • cardiomegaly due to myocardial damage and pericardial effusion

  • systemic venous distension

  • pleural effusions

  • lung opacity due to diffuse alveolar damage and haemorrhage

Treatment and prognosis

Without prompt treatment with corticosteroids, the mortality of all-trans-retinoic acid syndrome is about 25% 1. Early intervention with high dose corticosteroids is effective, and those most at risk are given steroid prophylaxis. Acute myeloid leukaemia treated with differentiation agents has a lower mortality rate compared to acute promyelocytic leukaemia treated with ATRA.

History and etymology

All-trans-retinoic acid syndrome was first described in 1991 by Frankel et al. 1-3,7.

Differential diagnosis

  • congestive heart failure

  • acute lung injury

  • fluid overload

See also

  • -<p><strong>All-trans-retinoic acid (ATRA) syndrome</strong>, is the more common cause of <strong>differentiation syndrome </strong><sup>8</sup>. <a href="/articles/acute-promyelocytic-leukemia">Acute promyelocytic leukaemia</a> (APL) cells respond to therapeutic levels of this normal plasma derivative of vitamin A by maturating into normal granulocytes which can cause capillary leakage and organ damage<sup> 1</sup>.</p><h4>Terminology</h4><p>More recently <strong>differentiation syndrome</strong> is the preferred term as other anti-leukaemia drugs are implicated. Arsenic trioxide (ATO) is often used in combination with ATRA and contributes to the development of this syndrome.</p><p>Isocitrate dehydrogenase (IDH) inhibitors cause this syndrome in <a href="/articles/acute-myeloid-leukaemia" title="Acute myeloid leukaemia">acute myeloid leukaemia</a> (AML) patients.</p><h4>Epidemiology</h4><p>Incidence is approximately 25% in APL patients treated with ATRA +/- ATO and 20% in AML patients treated with IDH inhibitors.</p><h4>Pathology</h4><p>Differentiation syndrome is related to the rapid increase in mature granulocytes over several days resulting in vascular adherence and organ infiltration. Cytokine release can cause capillary leak, haemorrhage and organ failure and these effects can be blocked by corticosteroids. Mortality can be as high as 25% and is commonly due to <a href="/articles/congestive-cardiac-failure" title="Heart failure">heart failure</a>, <a href="/articles/acute-respiratory-distress-syndrome-1" title="Acute respiratory distress syndrome">acute respiratory distress syndrome</a>, <a href="/articles/pulmonary-haemorrhage" title="Pulmonary haemorrhage">pulmonary haemorrhage</a> and renal failure<sup> 1</sup>.</p><h4>Clinical presentation</h4><p>Differentiation syndrome occurs approximately 7 days after treatment initiation with features of fever, congestive heart failure, fluid-retention, respiratory distress, haemorrhage, thrombosis and renal failure.</p><h4>Radiographic features</h4><p>Cardio-pulmonary disease dominates the radiographic picture.</p><h5>Plain radiograph</h5><p>Non-specific chest radiographic features can alert the clinical team to the possibility of differentiation syndrome: </p><ul>
  • +<p><strong>All-trans-retinoic acid (ATRA) syndrome</strong>, is the more common cause of <strong>differentiation syndrome </strong><sup>8</sup>. <a href="/articles/acute-promyelocytic-leukemia">Acute promyelocytic leukaemia</a> (APL) cells respond to therapeutic levels of this normal plasma derivative of vitamin A by maturating into normal granulocytes which can cause capillary leakage and organ damage<sup> 1</sup>.</p><h4>Terminology</h4><p>More recently <strong>differentiation syndrome</strong> is the preferred term as other anti-leukaemia drugs are implicated. Arsenic trioxide (ATO) is often used in combination with ATRA and contributes to the development of this syndrome.</p><p>Isocitrate dehydrogenase (IDH) inhibitors cause this syndrome in <a href="/articles/acute-myeloid-leukaemia" title="Acute myeloid leukaemia">acute myeloid leukaemia</a> (AML) patients.</p><h4>Epidemiology</h4><p>Incidence is approximately 25% in APL patients treated with ATRA +/- ATO and 20% in AML patients treated with IDH inhibitors.</p><h4>Pathology</h4><p>Differentiation syndrome is related to the rapid increase in mature granulocytes over several days resulting in vascular adherence and organ infiltration. Cytokine release can cause capillary leak, haemorrhage and organ failure and these effects can be blocked by corticosteroids. Mortality can be as high as 25% and is commonly due to <a href="/articles/congestive-cardiac-failure" title="Heart failure">heart failure</a>, <a href="/articles/acute-respiratory-distress-syndrome-1" title="Acute respiratory distress syndrome">acute respiratory distress syndrome</a>, <a href="/articles/pulmonary-haemorrhage" title="Pulmonary haemorrhage">pulmonary haemorrhage</a> and renal failure<sup> 1</sup>.</p><h4>Clinical presentation</h4><p>Differentiation syndrome occurs approximately 7 days after treatment initiation with features of fever, congestive heart failure, fluid-retention, respiratory distress, haemorrhage, thrombosis and renal failure.</p><h4>Radiographic features</h4><p>Cardio-pulmonary disease dominates the radiographic picture.</p><h5>Plain radiograph</h5><p>Imaging appearances are non-specific but can help to confirm the clinical suspicion of differentiation syndrome: </p><ul>
  • -</ul><h4>Treatment and prognosis</h4><p>Without prompt treatment with corticosteroids, the mortality of all-trans-retinoic acid syndrome is about 25% <sup>1</sup>. Early intervention with high dose corticosteroids is effective, and those most at risk are given steroid prophylaxis. Acute myeloid leukaemia treated with differentiation agents has a lower mortality rate.</p><h4>History and etymology</h4><p>All-trans-retinoic acid syndrome was first described in 1991 by Frankel et al. <sup>1-3,7</sup>.</p><h4>Differential diagnosis</h4><ul>
  • +</ul><h4>Treatment and prognosis</h4><p>Without prompt treatment with corticosteroids, the mortality of all-trans-retinoic acid syndrome is about 25% <sup>1</sup>. Early intervention with high dose corticosteroids is effective, and those most at risk are given steroid prophylaxis. Acute myeloid leukaemia treated with differentiation agents has a lower mortality rate compared to acute promyelocytic leukaemia treated with ATRA.</p><h4>History and etymology</h4><p>All-trans-retinoic acid syndrome was first described in 1991 by Frankel et al. <sup>1-3,7</sup>.</p><h4>Differential diagnosis</h4><ul>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.